search
Back to results

OPTIMIzing muScle Preservation in paTients wIth Cirrhosis (OPTIMISTIC)

Primary Purpose

Obesity, Compensated Cirrhosis, Sarcopenia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Continuous Energy Restriction (CER)
Alternate Day Modified Fasting (ADMF)
Group Health Education Sessions
Late Evening Snack
Physical activity
Self-monitoring
Remotely Supervised Exercise Sessions
Sponsored by
University of Kansas Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects ≥18 years of age. Per the NIH Policy NOT-OD-18-116, we will include adults ≥ 65 yrs.
  • Subjects have a BMI of 30-45. Body mass index (BMI) of 25 to 45 kg/m2. Individuals with a BMI< 25 kg/m2 are not overweight, and individuals with a BMI >45 kg/m2 require more aggressive weight-loss interventions such as bariatric surgery.

  • Subjects has a diagnosis of cirrhosis based on any of the following methods

    • Liver Biopsy is consistent with stage IV fibrosis according to the NASH Clinical Research Network (CRN) scoring system.
    • Fibroscan Liver Stiffness >14kpa
    • Endoscopy or imaging finding of varices

Exclusion Criteria:

  • Child-Pugh (CP) score currently > 6 (i.e., CP Class B/C cirrhosis).
  • History of ascites.
  • History of portal system encephalopathy.
  • Prior history of liver cancer.
  • Prior history of non-melanoma skin cancer within the last five years
  • Hepatitis C Virus (HCV) patients who have not undergone sustained virological response (SVR).
  • Hepatitis B Virus (HBV) Patients who have not received antiviral treatment.
  • Patients with diabetes currently on insulin and or sulfonylureas.
  • Active alcohol use >7 drinks per week in the past six months.
  • Suspected eating disorders based on Eating Attitudes Test (EAT-26) and The Binge Eating Scale (BES):
  • Unable to participate in moderate-intensity PA, e.g., brisk walking
  • Participation in a structured weight loss program in the previous six mos.
  • Not weight stable (5%) for three months prior to intake.
  • Unwilling to be randomized.
  • Pregnancy during the previous six mos., currently lactating, or planned pregnancy in the following six mos
  • Current use of antipsychotics, untreated depression, or other psychiatric illnesses would preclude weight management participation.
  • Adherence to specialized diets that would make it difficult or impossible to follow the guidelines for intervention.
  • Evidence of eating disorder or binge eating (as assessed by the Eating Attitudes Test and or Binge Eating Scale.)
  • Do not have access to a wireless equipment necessary for remotely delivered group and exercise classes.

Sites / Locations

  • University of Kansas Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Continuous Energy Restriction (CER)

Alternate-Day Moderate Fasting (ADMF).

Arm Description

Continuous energy restriction (CER; 1,200-1,500 kcal/day). Participants in both groups will have a daily late-evening snack and participate in remotely supervised exercises.

Alternate-Day Moderate Fasting (ADMF). Participants in both groups will have a daily late-evening snack and participate in remotely supervised exercises.

Outcomes

Primary Outcome Measures

Compare changes in body composition in both diets
The primary outcome is the percent of weight lost as fat-free mass at 24 weeks. Body weight and body composition (as assessed by dual x-ray absorptiometry) will be measured at baseline, week 12, and post-intervention. Percent weight loss from fat-free mass will be calculated as [Δ fat-free mass / Δ weight loss] for all participants who lose at least 3% of initial body weight. If >70% of participants lose at least 80% of weight from fat mass (or no more than 20% of weight loss coming from lean mass) we will proceed to testing this intervention in an adequately powered trial.

Secondary Outcome Measures

Frailty, Subjective
Karnofsky Performance Status (KPS). The KPS allows patients to be classified as to their functional impairment. This can be used to compare effectiveness of different therapies and to assess the prognosis in individual patients. The lower the KPS, the worse the survival for most serious illnesses.
Frailty, Objective
The Liver Frailty Index (LFI), composed of 3 performance-based tests (grip strength, chair stands, and balance), is a tool specifically developed in patients with cirrhosis to objectively measure physical function, a critical determinant of health outcomes.
Health Related Quality of Life
Health-related quality of life (HRQOL) is a multi-dimensional concept commonly used to examine the impact of health status on quality of life. HRQOL is often measured by four core questions that asked about general health status and number of unhealthy days.

Full Information

First Posted
May 2, 2022
Last Updated
February 7, 2023
Sponsor
University of Kansas Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05367596
Brief Title
OPTIMIzing muScle Preservation in paTients wIth Cirrhosis
Acronym
OPTIMISTIC
Official Title
OPTIMIzing muScle Preservation in paTients wIth Cirrhosis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
June 22, 2022 (Actual)
Primary Completion Date
December 16, 2022 (Actual)
Study Completion Date
December 16, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Kansas Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Patients with obesity and cirrhosis benefit from weight loss but are prone to sarcopenia (loss of muscle mass, strength, and function). This study proposes to test a specialized weight loss program Alternative-day Modified Fasting (ADMF) designed to promote weight loss and preserve skeletal muscle mass, strength, and function in patients with both Child-Pugh (CP) class A cirrhosis and obesity. This study will compare the effectiveness of the ADMF to Continuous Energy Restriction (CER) for 24-weeks. Both arms will receive a high-protein, high-BCAA diet, a late-night snack, supervised aerobic and resistance exercise, increased physical activity through self-monitoring, and group behavioral counseling. The primary aim of this trial is to evaluate the feasibility and acceptability of ADMF and CER for 6 months in patients with cirrhosis and obesity. The secondary aim is to compare changes in body composition in both diets.
Detailed Description
Patients with both cirrhosis and obesity benefit from weight loss, though patients with cirrhosis are prone to sarcopenia due to accelerated rates of protein turnover, and weight loss typically involves 20-30% of weight loss from lean mass. Prior research indicates that increased intake of high-quality protein, reduced fasting duration, and regular physical activity (particularly resistance training) can improve body composition in patients with cirrhosis. However, weight loss programming specifically tailored to retain lean mass in patients with cirrhosis has not been thoroughly investigated. Further, preliminary data suggests that alternate-day modified fasting, a form of intermittent fasting, may promote lean mass retention during weight loss. Here, this study will compare a weight loss program in patients with both Child-Pugh Class A cirrhosis and obesity using either a standard low-calorie diet (1,200 - 1,500 kcal/day) or alternate day modified fasting featuring a very-low-calorie diet 2-3 days per week for feasibility, satisfaction, and changes in body composition. Both groups will receive a behavioral weight loss program featuring portion-controlled meals and supervised group exercise.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Compensated Cirrhosis, Sarcopenia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized, controlled, open-label.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Continuous Energy Restriction (CER)
Arm Type
Experimental
Arm Description
Continuous energy restriction (CER; 1,200-1,500 kcal/day). Participants in both groups will have a daily late-evening snack and participate in remotely supervised exercises.
Arm Title
Alternate-Day Moderate Fasting (ADMF).
Arm Type
Experimental
Arm Description
Alternate-Day Moderate Fasting (ADMF). Participants in both groups will have a daily late-evening snack and participate in remotely supervised exercises.
Intervention Type
Behavioral
Intervention Name(s)
Continuous Energy Restriction (CER)
Intervention Description
Energy intake will be prescribed at approximately 1,200-1,500 kcal/day with high protein. The diet will consist of low-calorie shakes provided by the study, as well as commercially available portion-controlled entrées, fruits/vegetables, and low energy-density foods available in grocery stores.
Intervention Type
Behavioral
Intervention Name(s)
Alternate Day Modified Fasting (ADMF)
Intervention Description
Enhanced Care participants will have an alternate between three days of very-low energy intake (VLED; approximately 600-800 kcal/d) and four days of healthy eating (HE) each week. On HE days, participants will consume foods ad libitum for satiety.
Intervention Type
Behavioral
Intervention Name(s)
Group Health Education Sessions
Intervention Description
Using video conferencing, all participants will attend weekly approximately 45-60 minutes group health education sessions led by a registered dietitian. The session will deliver a comprehensive nutritional and lifestyle change program to promote lifestyle changes and improve compliance.
Intervention Type
Behavioral
Intervention Name(s)
Late Evening Snack
Intervention Description
The participants will have a late evening snack with a protein supplement.
Intervention Type
Behavioral
Intervention Name(s)
Physical activity
Intervention Description
All participants will be prescribed moderate-intensity aerobic activities that do not require access to specialized exercise facilities.
Intervention Type
Behavioral
Intervention Name(s)
Self-monitoring
Intervention Description
Weekly data related to adherence, food intake, physical activity, weight measurement, and nonserious adverse events will be self-reported via a REDCap survey. Participants will also be provided with a wireless activity tracker to measure total physical activity and intensity of activity objectively. These data will be used to counsel participants in addition to providing valuable feasibility data.
Intervention Type
Behavioral
Intervention Name(s)
Remotely Supervised Exercise Sessions
Intervention Description
Sessions of 45 minutes duration will be delivered via video conferencing 2-3 times per week.
Primary Outcome Measure Information:
Title
Compare changes in body composition in both diets
Description
The primary outcome is the percent of weight lost as fat-free mass at 24 weeks. Body weight and body composition (as assessed by dual x-ray absorptiometry) will be measured at baseline, week 12, and post-intervention. Percent weight loss from fat-free mass will be calculated as [Δ fat-free mass / Δ weight loss] for all participants who lose at least 3% of initial body weight. If >70% of participants lose at least 80% of weight from fat mass (or no more than 20% of weight loss coming from lean mass) we will proceed to testing this intervention in an adequately powered trial.
Time Frame
Baseline, 12 weeks and 24 weeks.
Secondary Outcome Measure Information:
Title
Frailty, Subjective
Description
Karnofsky Performance Status (KPS). The KPS allows patients to be classified as to their functional impairment. This can be used to compare effectiveness of different therapies and to assess the prognosis in individual patients. The lower the KPS, the worse the survival for most serious illnesses.
Time Frame
Baseline, 12 weeks and 24 weeks.
Title
Frailty, Objective
Description
The Liver Frailty Index (LFI), composed of 3 performance-based tests (grip strength, chair stands, and balance), is a tool specifically developed in patients with cirrhosis to objectively measure physical function, a critical determinant of health outcomes.
Time Frame
Baseline, 12 weeks and 24 weeks.
Title
Health Related Quality of Life
Description
Health-related quality of life (HRQOL) is a multi-dimensional concept commonly used to examine the impact of health status on quality of life. HRQOL is often measured by four core questions that asked about general health status and number of unhealthy days.
Time Frame
Baseline, 12 weeks and 24 weeks.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects ≥18 years of age. Per the NIH Policy NOT-OD-18-116, we will include adults ≥ 65 yrs. Subjects have a BMI of 30-45. Body mass index (BMI) of 25 to 45 kg/m2. Individuals with a BMI< 25 kg/m2 are not overweight, and individuals with a BMI >45 kg/m2 require more aggressive weight-loss interventions such as bariatric surgery. Subjects has a diagnosis of cirrhosis based on any of the following methods Liver Biopsy is consistent with stage IV fibrosis according to the NASH Clinical Research Network (CRN) scoring system. Fibroscan Liver Stiffness >14kpa Endoscopy or imaging finding of varices Exclusion Criteria: Child-Pugh (CP) score currently > 6 (i.e., CP Class B/C cirrhosis). History of ascites. History of portal system encephalopathy. Prior history of liver cancer. Prior history of non-melanoma skin cancer within the last five years Hepatitis C Virus (HCV) patients who have not undergone sustained virological response (SVR). Hepatitis B Virus (HBV) Patients who have not received antiviral treatment. Patients with diabetes currently on insulin and or sulfonylureas. Active alcohol use >7 drinks per week in the past six months. Suspected eating disorders based on Eating Attitudes Test (EAT-26) and The Binge Eating Scale (BES): Unable to participate in moderate-intensity PA, e.g., brisk walking Participation in a structured weight loss program in the previous six mos. Not weight stable (5%) for three months prior to intake. Unwilling to be randomized. Pregnancy during the previous six mos., currently lactating, or planned pregnancy in the following six mos Current use of antipsychotics, untreated depression, or other psychiatric illnesses would preclude weight management participation. Adherence to specialized diets that would make it difficult or impossible to follow the guidelines for intervention. Evidence of eating disorder or binge eating (as assessed by the Eating Attitudes Test and or Binge Eating Scale.) Do not have access to a wireless equipment necessary for remotely delivered group and exercise classes.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Winston Dunn, MD
Organizational Affiliation
KUMC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Felicia Felicia Steger, PhD
Organizational Affiliation
KUMC
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Kansas Medical Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

OPTIMIzing muScle Preservation in paTients wIth Cirrhosis

We'll reach out to this number within 24 hrs